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Wound Irrigation in Initial Management of Open Fractures
To the Editor: In reporting on the results of the 
Fluid Lavage of Open Wounds (FLOW) trial, 
Bhandari et al. (Dec. 31 issue)1 describe the ini-
tial management of open fracture wounds. Ac-
cording to their protocol, the investigators aimed 
to perform irrigation and débridement for skin 
and soft-tissue defects or to close wounds that 
had delayed union or nonunion with the use of 
grafting or muscle flaps within 7 to 14 days after 
the initial surgery. The use of low-pressure wound 
therapy (vacuum-assisted closure) was described. 
We wonder whether the investigators adhered to 
the protocol regarding definitive wound cover-
age, and we wonder about the number and dura-
tion of vacuum-assisted closure procedures used 
in the trial, since the application of these tech-
niques is controversial.
Delayed wound healing may result in exoge-
nous superinfection, which is often polymicro-
bial.2 In our experience, superinfection is not 
prevented but may be facilitated by prolonged 
vacuum-assisted closure therapy.3 Skin flora mi-
croorganisms can migrate into the wound and 
adhere to internal fixation material, leading to 
nonunion or a high rate of recurrent infection.4
One of the primary end points of the trial was 
reoperation at the operative site within 12 months 
after the initial procedure in order to treat an 
infection. Information on the number and dura-
tion of vacuum-assisted closure procedures used 
in the trial might provide valuable insight into 
the association of the use of this procedure with 
later infection.
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To the Editor: Bhandari et al. analyzed the ef-
fectiveness of irrigation in the management of 
open fracture wounds and found no difference in 
the primary trial end-point event (reoperation 
within 12 months after the index procedure in 
order to treat an infection, manage a wound-
healing problem, or promote bone healing) ac-
cording to the type of irrigation pressure used. 
However, the rate of reoperation was higher in 
the soap group than in the saline group.
Even if large-volume irrigation is always rec-
ommended, débridement is the most important 
procedure to perform. Adequate débridement is 
thought to be key to reducing the prevalence of 
infection after open fracture.1-3 However, infor-
mation regarding débridement practices is lack-
ing in the protocol for the FLOW trial. How was 
the quality of the initial débridement evaluated 
by surgeons? Débridement should be extensive 
in patients with Gustilo–Anderson type III frac-
tures but limited in patients with Gustilo–An-
derson type I fractures (the Gustilo–Anderson 
classification ranges from type I to type III, with 
higher numbers indicating greater injury and a 
higher potential for complications).4 Culture 
specimens should be obtained from the wound 
after initial débridement, as well as before and 
after irrigation at each operative procedure, in 
order to assess the reduction of the bacterio-
logic load according to the type of irrigation 
pressure used.
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The authors reply: Sendi and McNally inquire 
about vacuum-assisted closure of wounds in the 
FLOW trial. A post hoc analysis indicated that 
331 patients underwent a vacuum-assisted clo-
sure in our trial. Although we did not stratify 
patients according to the use or nonuse of vacu-
um-assisted closure, the study groups (the irriga-
tion-pressure groups and the solution groups) 
were balanced with respect to the use of the vac-
uum-assisted technique.
As expected, the use of vacuum-assisted clo-
sure was directly proportional to the severity of 
the open fracture wound (according to the 
Gustilo–Anderson fracture type). In all types of 
fracture wounds, the use of vacuum-assisted 
wound closure was associated with an increased 
rate of infection (by a factor of 5.3 among pa-
tients with type I wounds, a factor of 2.4 among 
patients with type II wounds, a factor of 2.0 among 
patients with type IIIA wounds, and a factor of 
1.5 among patients with type IIIB wounds) (Ta-
ble 1).
A new analysis of factors associated with 
rates of reoperation is currently a priority for the 
prespecified secondary analysis of our data set. 
This analysis of factors includes wound closure 
and management as a covariate among several 
other variables. The extent to which vacuum-assist-
ed wound closure predicts infection within 1 year 
after fracture may be of interest in future trials. 
Exploration of the biologic rationale for this 
observation is warranted.
In reply to Barbier and Pasquier: our trial 
carefully evaluated approaches to wound irriga-
tion as procedures included in the composite 
primary end point. However, removal of all non-
viable skin, muscle, and other tissues, also called 
wound débridement, was standardized to the ex-
tent feasible in our global pragmatic trial. Al-
though the approach to débridement was left to the 
discretion of the operating surgeon, we encour-
aged a thorough approach consistent with the 
standard of care. Indeed, similar amounts of skin, 
muscle, fascia, and bone were débrided in patients 
across the treatment groups; as expected, these 
amounts increased with the severity of fracture 
wounds. Furthermore, our trial did stratify pa-
tients according to the severity of open wounds 
to ensure a balance across treatment groups with 
respect to the most severe types of wounds.
Gustilo–Anderson 
Type† Vacuum-Assisted Closure No Vacuum-Assisted Closure P Value‡
Infection No Infection Infection No Infection
no. of patients/total no. (%) no. of patients/total no. (%)
I 3/10 (30.0) 7/10 (70.0) 36/629 (5.7) 593/629 (94.3) NA
II 17/62 (27.4) 45/62 (72.6) 93/834 (11.2) 741/834 (88.8) <0.001
IIIA 37/130 (28.5) 93/130 (71.5) 76/519 (14.6) 443/519 (85.4) <0.001
IIIB 41/130 (31.5) 88/130 (67.7) 22/103 (21.4) 81/103 (78.6) <0.001
*  NA denotes not applicable.
†  The Gustilo–Anderson classification ranges from type I to type III, with higher numbers indicating greater injury and a 
higher potential for complications.
‡  The comparisons of the use or nonuse of vacuum-assisted closure of wounds and fracture type with the rate of infec-
tions were analyzed with the use of multivariable binary logistic regression. P<0.001 for the comparison of vacuum- 
assisted closure of wounds with no vacuum-assisted closure (odds ratio, 2.39; 95% confidence interval, 1.76 to 3.26) 
with adjustment for Gustilo–Anderson fracture type.
Table 1. Rate of Infection, According to the Method of Wound Closure and Fracture Type.*
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Crizotinib Resensitization by Compound Mutation
To the Editor: Shaw et al. (Jan. 7 issue)1 report 
a case of anaplastic lymphoma kinase (ALK)–pos-
itive non–small-cell lung cancer that was suc-
cessfully re-treated with crizotinib; in their re-
port, the authors show the importance of repeat 
biopsy in patients with lung cancer treated with 
targeted therapies. In fact, the expansion of a 
double ALK mutant clone (p.C1156Y–p.L1198F) 
led to a restored sensitivity to crizotinib that re-
sulted in a dramatic response after the disease 
had progressed during ceritinib and lorlatinib 
therapies. However, because of unreachable sites 
of disease, not many patients can undergo repeat 
biopsies. Circulating cell-free DNA could repre-
sent a useful source for molecular profiling in 
patients with ALK-positive non–small-cell lung 
cancer, as it does in patients with epidermal growth 
factor receptor (EGFR)–mutated non–small-cell 
lung cancer.2 We monitored plasma DNA before 
and during therapy with brigatinib (another ALK 
inhibitor) in patients who had tumors that had 
progressed during treatment with crizotinib; we 
isolated the mutation p.L1196M alone in one pa-
tient and p.L1196M associated with p.G1269A in 
another patient. The DNA levels of both muta-
tions decreased during therapy, which correspond-
ed to excellent radiologic responses. A third patient 
had an ALK p.F1174L mutation detected in circu-
lating cell-free DNA after 2 months, but the pa-
tient has not yet had disease progression. In con-
clusion, molecular profiling of ALK-positive tumors 
is crucial, and circulating cell-free DNA represents 
a valid source to monitor.
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The authors reply: In our case report, we stud-
ied the evolution of resistance to multiple, differ-
ent ALK-targeted therapies using serial tumor bi-
opsies. We agree that repeat biopsies are not 
always practical or technically feasible and that 
circulating cell-free DNA holds great promise of 
real-time, noninvasive monitoring of genetic re-
sistance mechanisms. Although the resistant 
cancer in our patient was remarkably homoge-
neous, cancers in other patients can show consid-
erable heterogeneity at the time of resistance.1-3 In 
patients with heterogeneous cancer, repeat biop-
sies may provide limited information because 
only a single site of disease is sampled. In con-
trast, circulating cell-free DNA can theoretically 
identify genetic resistance mechanisms across 
multiple sites of disease and thus may be particu-
larly helpful in evaluating the scope and effect of 
tumor heterogeneity. Future clinical studies may 
help to establish the effectiveness of emerging 
cell-free DNA technologies in identifying clini-
cally relevant mechanisms of resistance.
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